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d We describe the immunogenomics landscape of 14 pediatric
extracranial solid tumors
d Immunophenotype is prognostic of survival in neuroblastoma
and osteosarcoma
d We identify multiple targets for immune therapy
d Immune targeting ofPRAME demonstrates in vitro and in vivo
cytotoxicity
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Brohl et al. perform immunogenomics
analysis of a cohort of 788 pediatric
extracranial solid tumors and cell lines,
representing 14 diagnoses, utilizing RNA
sequencing. They broadly describe
prognostically relevant
immunophenotypes and provide proof of
concept of a transcriptomics-informed
adoptive cellular therapy approach,
validating PRAME as a multi-pediatric
cancer immunotherapy target.
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We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extra-
cranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes of 131 pedi-
atric cancer cell lines and 147 normal tissue samples for comparison. We describe patterns of infiltrating
immune cells, T cell receptor (TCR) clonal expansion, and translationally relevant immune checkpoints.
We find that tumor-infiltrating lymphocytes and TCR counts vary widely across cancer types and within
each diagnosis, and notably are significantly predictive of survival in osteosarcoma patients. We identify po-
tential cancer-specific immunotherapeutic targets for adoptive cell therapies including cell-surface proteins,
tumor germline antigens, and lineage-specific transcription factors. Using an orthogonal immunopeptido-
mics approach, we find several potential immunotherapeutic targets in osteosarcoma and Ewing sarcoma
and validated PRAME as a bona fide multi-pediatric cancer target. Importantly, this work provides a critical
framework for immune targeting of extracranial solid tumors using parallel immuno-transcriptomic and -pep-
tidomic approaches.
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Pediatric malignancies remain the leading cause of disease-
related death in children in the United States. While advances
in multidisciplinary treatment in the later parts of the 20th century
resulted in significant improvements in survival from pediatric
cancer, further progress over the last several decades has
been modest (Howlader et al., 2014). For most pediatric malig-
nancies, especially solid tumors, survival remains poor for those
with relapsed or advanced disease.
Rarity and heterogeneity make pediatric cancers chal-
lenging to study and treat. Increasingly, there is a desire to
apply high-throughput analytical techniques to better charac-
terize tumor’s molecular composition for precision therapeu-
tics. Recently, two large next-generation sequencing studies
have helped to provide the landscape of the most common
mutational drivers across a range of pediatric cancers (Gröb-
ner et al., 2018; Ma et al., 2018). While these studies form a
foundation for our molecular understanding of these malig-
nancies, further work is needed to enable translation to the
clinic.
In recent years, immunotherapy has revolutionized the
treatment approach for an increasing number of adult cancer
types. These clinical breakthroughs have led to a heightened
interest in understanding the molecular basis for immuno-
therapy response. To further our understanding of the
immunogenomic landscape in pediatric malignancies, we per-
formed an analysis of whole-transcriptome sequencing of 657
extracranial solid tumor specimens, representing 14 major
cancer diagnoses. A comprehensive analysis of the immuno-
genomic features of these tumors was performed including tu-
mor microenvironment and immune infiltration pattern with
quantification, expression pattern of immune checkpoint
genes, tumor-specific genes, and intratumoral T cell receptor
(TCR) repertoire. We further provided orthogonal confirmation
of transcriptomics findings of immunotherapeutic targets by
evaluating the immunopeptidome of osteosarcoma and Ewing
sarcoma and demonstrated proof-of-concept in vitro and
in vivo cytotoxicity using a transcriptomics-informed adoptive
cell therapy (ACT) approach.
RESULTS
Whole-transcriptome sequencing analysis was performed on
657 tumor samples from 623 pediatric or young adult patients
diagnosed with an extra-cranial solid malignancy. In parallel,
RNA sequencing was performed on 131 commonly used can-
cer cell lines and 147 normal tissues representing 21 organs
(Table 1; Table S1A). Quality metrics of the sequencing data
are summarized in Table S1B and S1C. Fourteen different di-
agnoses, including sub-categories of neuroblastoma (NB;
MYCN amplified and not amplified) and rhabdomyosarcoma
(RMS; fusion positive and negative) were represented
(Table 1; Table S1A). Mirroring the relative disease incidence
of extracranial pediatric solid malignancies seen at our sites,
the majority of our cohort comprised one of four diagnoses:
neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and
osteosarcoma.
Tumor immune microenvironment
To characterize the immune microenvironment in pediatric solid
tumors, we performed tumor profiling of infiltrating immune
cells using predefined immune gene sets, including CIBER-
SORT, immune, and stromal signatures where enrichment
scores for immune cell subtypes as well as a described overall
‘‘immune signature’’ in each tumor sample were calculated
(Newman et al., 2015; Yoshihara et al., 2013). First, we as-
sessed enrichment scores for immune cell types and gene sig-
natures in each tumor in the context of its tumor type (Figure 1A)
and observed diverse enrichment of immune signatures among
different types of tumors. There was a strong correlation be-
tween immune signature score and enrichment for all immune
cell subtypes (Figure 1A). Interestingly, there was a notable
clustering of fusion-driven malignancies such as Ewing sar-
coma (EWS), fusion-positive RMS, synovial sarcoma (SS),
clear cell sarcoma of kidney (CCSK), and desmoplastic small
round cell tumor (DSRCT) as having low median infiltrating im-
mune cell enrichments relative to other tumor types in the anal-
ysis. A notable exception to this pattern is alveolar soft part sar-
coma (ASPS), which had the highest median immune signature
score among tumor types in our cohort despite being a fusion
driven malignancy. On the other hand, tumor types with the
highest relative median immune cell enrichment include dis-
eases reported to have ‘‘complex’’ genomes including osteo-
sarcoma (OS), melanoma (ML), and undifferentiated sarcoma
(UDS) (Figure 1A).
To compare pediatric tumors with adult malignancies, we per-
formed a combined analysis of our cohort with publicly available
data from The Cancer Genome Atlas (TCGA). For the overall im-
mune signature scores, all pediatric tumor subtypes displayed
modest or below median immune signature scores with corre-
sponding modest CD8+ T cell enrichment relative to adult tumor
counterparts, with the notable exception of ASPS, whichwas the
only pediatric tumor to fall within the top quartile of median
enrichment (Figure 1B; Figure S1). Remarkably, ASPS displayed
the highest levels of human leukocyte antigen A (HLA-A) expres-
sion across all tumor types evaluated, including TCGA adult tu-
mors (Figure S1). These results are notable in light of the recent
clinical observation that ASPS is one of the most clinically
responsive tumor types to checkpoint inhibitor therapy (Wilky
et al., 2019), and the association between expression of major
histocompatibility complex (MHC) molecules and efficacy of
checkpoint inhibitory therapies (Yuasa et al., 2017).
We next sought to evaluate the potential impact of tumor im-
mune microenvironment on prognosis. For this analysis, we uti-
lized the osteosarcoma patient cohort as outcomes data were
available for this subgroup in our cohort (Table S1D). Of note,
all tumor samples used for this analysis were taken from the pri-
mary tumor prior to any chemotherapy. Remarkably, similar to
our previously reported association between high immune cell
infiltrate enrichment and favorable prognosis in neuroblastoma
(Wei et al., 2018), we found that increased expression of immune
cell markers in the tumor microenvironment of these pre-treat-
ment osteosarcoma tumors were significantly associated with
amore favorable outcome (Figures 1C and 1D). The associations
remain highly significant in cox-regression analysis to account
for metastatic status, indicating that the presence of CD8+




T cells in pre-treatment primary tumors is an independent pre-
dictor for patient outcome (Figure S2).
Immune checkpoint expression
Given the rapid development of checkpoint inhibitor therapy
across many tumor types, expression of immunoinhibitory mol-
ecules (e.g., CD274 or PD-L1) is of translational interest. Similar
to the immune cell infiltrate enrichment patterns, we observed
heterogeneity in the expression of immune checkpoint genes
both within and across tumor types (Figure 2A; Figure S3).
Consistent with its sensitivity to immune checkpoint blockade,
ASPS demonstrated the highest median expression of PD-L1
suggesting a dependency on this immune checkpoint for im-
mune evasion (Figure 2A). To further evaluate for immune check-
points that might be the most clinically relevant in our cohort, we
performed a correlation analysis between the expression of indi-
vidual immune checkpoint genes and CD8+ T cell infiltrate
enrichment within cancer types to look for the co-occurrence
of these two features. Interestingly, we observed two patterns
of immune checkpoint expression correlates to CD8+ T cell infil-
trate enrichment (Figure 2B). First was a cluster of cancer types
including NB, EWS, DSRCT, OS, and RMS in which the majority
of checkpoint genes evaluated are significantly correlated with
tumor-infiltrating CD8+ T cells (Spearman rank correlation >0.3;
adjusted p < 0.05). On the contrary, in the remaining tumor types
including ASPS, a much narrower set of immune modulating
genes are significantly associated with tumor-infiltrating CD8+
T cells (Figure 2B).
Expanding on our prior observations in neuroblastoma (Wei
et al., 2018), we noted appreciable differences in TIL enrichment
pattern (Figure 1A) and expressional levels of immune check-
points between MYCN-not amplified (MYCN.NA) and MYCN-
amplified (MYCN.A) tumors (Figure 2A). To validate these find-
ings at the protein level, we performed immunoprofiling using
multiplex NanoString digital spatial profiling technology on a
neuroblastoma tissue array containing 33 independent neuro-
blastoma tumors of which 9 were MYCN.A and 24 were
MYCN.NA (Wei et al., 2018). Consistent with the RNA
sequencing (RNA-seq) data, the protein-expression levels of
TIL infiltrate markers and immune checkpoints are generally
elevated in MYNC.NA tumors compared to MYCN.A tumors
(Figure 2C).
Despite disappointing early trials with immune checkpoint in-
hibitors, osteosarcoma has been proposed as a potentially im-
mune responsive tumor due to favorable immunogenomic char-
acteristics, including relatively high immune cell infiltration when
Table 1. Sample cohort
Tumor samples Normal samples
Diagnosis and subtype Tumor count Cell line count Subtotal Tissue type Count
Alveolar soft part sarcoma (ASPS) 16 3 19 adrenal gland 8
Clear cell sarcoma of kidney (CCSK)a 16 0 16 bladder 8
Desmoplastic small round cell tumor (DSRCT) 40 0 40 cerebellum 10
Ewing sarcoma (EWS)b 79 43 122 cerebrum 8
Hepatoblastoma (HBL) 30 0 30 colon 9
Melanoma (ML) 6 0 6 heart 7
Neuroblastoma (NB)c ileum 8
MYCN-amplified (NB.MYCN.A) 47 28 75 kidney 8
MYCN-not amplified (NB.MYCN.NA) 147 12 159 liver 8
Unknown (NB.Unknown) 12 0 12 lung 8
Osteosarcoma (OS)d 93 9 102 muscle 5
Rhabdomyosarcoma (RMS)e ovary 5
Fusion-negative (RMS-FN) 60 21 81 pancreas 6
Fusion-positive (RMS-FP) 38 12 50 prostate 9
Synovial sarcoma (SS) 31 3 34 skeletal muscle 6
Teratoma 4 0 4 spleen 5
Undifferentiated sarcoma (UDS) 6 0 6 stomach 7
Wilms tumor (WT) 27 0 27 testis 7
Yolk sac tumor (YST) 5 0 5 thyroid 1
ureter 7
uterus 7
Total 657 131 788 147
aData are available in dbGaP: phs000466.
bData are available in dbGaP: phs000768.
cData are available in dbGaP: phs000467.
dData are available in dbGaP: phs000468.
eData are available in dbGaP: phs000720.
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compared to other pediatric cancer types. We then selected os-
teosarcoma to further validate the presence of immune cell types
and immune checkpoint expression as predicted by RNA-seq.
Multiplexed immunohistochemistry was performed for a panel
of immune markers in an independent cohort of 25 osteosar-
coma tumors. Consistent with the RNA-seq prediction and the
previous findings in a subset of TARGET osteosarcoma cohort
(Wunder et al., 2020), there were robust infiltrating T cells
(markers CD3, CD8) andM2macrophages (CD163), with moder-
ate PD-L1 expression in these osteosarcoma samples (Fig-
ure S4). On the other hand, relative to other pediatric solid tumor
types, we observed osteosarcoma to exhibit pronounced
expression of additional immunosuppressive molecules particu-
larly TGFB1 andCSF1R, wheremedian expression was the high-
est among all tumor types in the study cohort (Figure S3).
T cell receptor repertoire
To further characterize the immunologic landscape of pediat-
ric solid tumors, we performed an analysis of the T cell recep-
tor (TCR) repertoire utilizing a computational method for de
novo assembly of hypervariable region sequences from com-
plementary-determining region 3 (CDR3) (Li et al., 2016). In
total, we identified 35,897 unique T cell receptor beta-chain
(TCR-b)-CDR3 sequences across our tumor cohort (Figure 3A;
Table S2). Of note, MYCN-not-amplified NB and ASPS had the
highest median TCR-b counts among the tumor types studied,
in keeping with their responsiveness to immune therapy. The
CDR3 sequences had lengths ranging from 6 to 25 amino
acids with a median length of 14 (Figure S5A). The sequence
patterns for the most frequent 14-amino-acid CDR3 sequence
were very similar to that previously reported across a large
Figure 1. Tumor immune microenvironment of pediatric solid tumors
(A) Global pattern of enrichment of various immune signatures across cancer types. Tumor typeswith a sample size of >5 are shown. The heatmap corresponds to
the percentage of tumors with a positive enrichment score for the immune cell subtype by ssGSEA.
(B) Distribution of immune signature enrichment scores across cancer types included in this study (colored) as compared to adult tumor samples in the TCGA
project (gray).
(C and D) Kaplan-Meier (KM) plots of overall survival demonstrate that patients with tumors of high immune score (C) or high CD8+ T cell score (D) are significantly
associated with a favorable prognosis in the osteosarcoma cohort where outcome data are available.
A
B C
Figure 2. Immune checkpoint expression in pediatric solid tumors
(A) Expression of selected immune checkpoint genes across tumor types. Dots represent the median expression for each cancer type.
(B) Correlation of immunomodulatory gene expression and CD8+ T cell infiltrate. Fill indicates significant association (Spearman rank correlation >0.3; adjusted
p < 0.05) within that cancer type. Highlighted genes in the blue font represent targets of antibody therapies approved by FDA or currently in clinical trial.
(C) Protein expression of an immune gene panel on an independent neuroblastoma tissue array (Wei et al., 2018) using a multiplex protein detection assay reveal
consistent findings of differential expression of immune cell markers betweenMYCN-amplified (MYCN.A) andMYCN-not amplified (MYCN.NA) tumors. The scale
bar represents Z-scored standardized protein-expression level.




set of adult cancers (TCGA) as well as in the peripheral blood
of healthy donors (Figure S5) (Li et al., 2016; Warren et al.,
2011).
We next compared TCR sequences identified within our tumor
cohort to those identified across the TCGA database (Li et al.,
2016), to those identified in normal tissues from our study cohort,
and to those reported in two healthy donor population databases
(Shugay et al., 2018; Warren et al., 2011) (Table S2; Figure S5F).
Of the 35,897 total TCRs identified across our tumor cohort,
29,381 (84.7%) were unique to a single tumor and not present
in the comparator databases, 5,327 (15.3%) overlapped with
one of the healthy adult databases or normal tissues. Of note,
out of 194 shared TCR sequences in 2 or more tumors, 165, rep-
resented by unique protein sequences, were shared in 2 or more
patients within our cohort and not present in the comparator
healthy population databases, which may represent tumor tar-
geting TCRs (Table S2; Figure S5F).
We evaluated the potential impact of intra-tumoral TCR
burden (measured as TCR counts) on outcome in the OS cohort
where clinical data were available. Similar to our analysis of im-
mune score and CD8+ T cell infiltrate enrichment, we found
that patients with a high TCR clone burden in these pre-treat-
ment samples were significantly associated with a more favor-
able prognosis (Figure 3B), which was independent of the meta-
static status of the patient (Figure S2).
To evaluate for possible clonal expansion of TCRs, we deter-
mined the abundance of each CDR3 clone (counts/million) as
well as the relative contribution of each TCR clone to the total
TCR counts found in each tumor. Indeed, we noted several tu-
mors that had evidence of high intra-tumoral TCR burden with
varying degrees of TCR diversity (Figure 3C). When quantifying
expanded TCR clones as defined by both high expression
(>99th percentile) and high relative contribution to total intra-tu-
moral TCR count in a given tumor (>1%), we observed 36/623
(5.8%) of patients (range 0%–26.7% per cancer type) having a
tumor that met our criteria for intra-tumoral clonal T cell expan-
sion (Figure 3D). Interestingly, ASPS and OS, which we also
identified as having high relative enrichment of immune cell infil-
trate and high median immune signature scores, were found to
have the highest percentage of expanded intra-tumoral TCR
clones, in 26.7% and 22.0% of patients, respectively. We did
not find evidence of TCR clonal expansion in any tumor samples






Figure 3. Intra-tumoral T cell receptor b (TCR-b) repertoire identified using RNA-seq data in pediatric solid tumors
(A) Number of unique complementary-determining region 3 (CDR3) detected in each tumor. Red bars represent median for each cancer type.
(B) Kaplan-Meier analysis of available outcome data in the osteosarcoma cohort demonstrates that patients with a high TCR-b count are significantly associated
with favorable outcome (p < 0.01).
(C) In order to investigate T cell clone expansion in individual tumors, TCR-b clones are ranked by their abundance on the x axis and the normalized clone count is
plotted on the y axis. Each line represents all TCR-b clones detected in a single tumor and clearly shows evidence of high clonal expansion of some TCRs.
(D) Clonal expansion of TCR-bs. Each dot represents a TCR-b clone in a tumor sample. The highlighted region depicts expanded TCR-b clones as evidenced by
high normalized clone count (>99th percentile) and high relative contribution to the total intra-tumoral TCR-b count (>1%). The accompanying table details the
percentage of tumors with R1 clonally expanded TCR-b. *Total tumor/patient count and calculated percentages include all patients in the study cohort.




Expression of cell-surface proteins, transcription
factors, and tumor germline antigens
To discover potential targets for immunotherapy, we performed
differential gene-expression analysis comparing each cancer
type to 147 normal tissue samples (excluding testis and ovary)
using stringent criteria of p % 0.00001 with a fold change R16
compared to normal. We first identified cancer-specific cell-sur-
face genes that may be targets for Chimeric Antigen Receptor
T cell (CART) or antibody-based therapies. This approach iden-
tified 107 cell-surface genes (Figure 4A; Table S3A), with notable
findings including GPC2, ALK, and FGFR4, which are being
developed in preclinical or clinical studies as targets for CART
therapies by our group and others (Richards et al., 2018). To
identify other genes that may be a potential source of immunore-
activity for adoptive cellular therapy (ACT), we also performed a
similar analysis for transcription factors and tumor germline an-
tigens (TGAs) to identify those that are robustly expressed in tu-
mors but show low or absent expression in normal tissues. We
identified 88 transcription factors, many of which have been
described previously as part of the core regulatory transcription
factor circuitry in specific cancer types, such as PHOX2B,
TWIST1, and ISL1 in neuroblastoma (Durbin et al., 2018; Selmi
et al., 2015);MYOD1 andMYOG in rhabdomyosarcoma (Gryder
et al., 2017); NR0B1 in Ewing sarcoma (Kinsey et al., 2006) (Fig-
ure 4B; Table S3B). For TGAs, we identified 43 genes, including
those that are currently under clinical investigation as ACT tar-
gets such as NY-ESO-1 (CTAG1A) in synovial sarcoma (D’An-
gelo et al., 2018b), and PRAME in a number of histologic types
(Gutzmer et al., 2016; Luk et al., 2018) (Figure 4C; Table S3C).
Although the median expression of these potential immunother-
apeutic targets was high in various cancer types, their expres-
sion was not uniform across all tumors (Figure 4D).
To evaluate whether currently available cell line models exhibit
expression of cancer-specific potential immunotherapy targets
congruent to that observed in patient tumors, we evaluated tran-
scriptome sequencing of a panel of 131 commonly utilized cell
lines. For top hits GPC2, FOXM1, and PRAME, cell line expres-
sion was similar to the corresponding tumors of the same histol-
ogy (Figure S6A). More broadly, we report the expression data
for commonly used cell lines representative of their respective
cancers for ASPS, EWS, NB.MYCN.A, NB.MYCN.NA, OS,
RMS.FP, RMS.FN, and SS, enabling researchers to identify suit-
able cell lines for further study based on gene-expression
level of specific immune targets (Table S3; https://omics-
oncogenomics.ccr.cancer.gov/cgi-bin/JK).
Of tumor germline antigens, we identified PRAME as a poten-
tial multi-pediatric cancer target, expressed in many of the tumor
types but showing minimal to no expression in all normal organs
except testes and ovaries (Figures 4C and 4D). High protein
expression of PRAME in neuroblastoma (Oberthuer et al.,
2004) and osteosarcoma (Tan et al., 2012) have previously
been reported. To validate expression in additional tumor types,
we performed immunohistochemistry (IHC) of PRAME on an in-
dependent panel of pediatric solid tumors and patient derived
xenografts (PDXs), which confirmed its robust expression in
7/12 (58%) samples (Figure S6D). Representative images are
shown for OS, EWS, fusion-negative RMS, and control tissues
(Figure 4E; Figure S6).
Identification of targetable tumor antigens in OS and
EWS using immunopeptidome
To further validate our RNA-seq findings of cancer-specific anti-
gens and understand how these antigens might be presented
by MHC class I complexes, we performed immunopeptidome
(HLA-Ligandome) analysis using MHC class I immunoprecipita-
tion (IP), peptide elution, and identification using LC-MS/MS on
HLA*A2:01 positive cell lines (Figure S7). We focused on OS
and EWS as these are among the most common pediatric sar-
comas and remain a significant therapeutic challenge for meta-
static disease. Integration of our transcriptomic and immuno-
peptidomic analyses revealed high-affinity peptides derived
from tumor-associated genes such as PRAME, PBK, and several
MAGE gene family genes (Table 2). Several of these MHC class I
peptides were also observed in immune-responsive adult malig-
nancies and have been successfully targeted using engineered
T cells with adoptive cell transfer (Table 2; Table S4).
Among the peptides identified, we identified two HLA*A2:01
restricted peptides (ALLPSLSHC, SLLQHLIGL) derived from the
PRAMEprotein (Table2;TableS4).Asaproofofconcept for target-
ing PRAME, we tested a previously reported TCR targeting the
PRAMEHLA*A2:01peptideSLLQHLIGL (Amiretal., 2011).Healthy
donor T cells expressing thePRAMETCRshowedcytotoxicity and
cytokine production when co-cultured with U2OS (Figure S7), an
osteosarcoma cell line that we found to present SLLQHLIGL on
HLA*A2:01. To improve activity and specificity, we modified the
PRAME TCR by swapping the TCR constant domains with the
murine equivalent and adding cysteine linkers to improve exoge-
nousTCR-a-TCR-bpairing (Cohenetal., 2006, 2007) (herein called
murPRAME-TCR). We next engineered SAOS2 (OS) and TC32
(EWS) cells expressing a reporter luciferase:mCherry (negative
control) or luciferase:PRAME (positive control) (Figure 5A).
SAOS2 and TC32 cell lines were selected for their high expression
of HLA*A2:01 (Figure S7A) and lack of endogenous PRAME
expression, allowing us to test the specificity of the murPRAME-
TCR. Co-culture of these lines with the murPRAME-TCR cells
had no significant effect on either control cell line expressing luci-
ferase:mCherry (Figure 5B, top).However,weobservedsignificant
cytotoxicity against SAOS2 and TC32 expressing PRAME from
murPRAME-TCR T cells (Figure 5B, bottom).
Last, we tested whether murPRAME-TCR T cells could have
therapeutic potential as an adoptive cell therapy in vivo using
an aggressive metastatic EWS mouse model with intravenous
delivery of PRAME-expressing TC32 cells (Figure 5C). After
engraftment, mice were randomized and treated with vehicle
(Hank’s balanced salt solution [HBSS]), untransduced T cells
(UTD), or murPRAME-TCR-transduced T cells (Figure 5C). Saline
and UTD-treated mice displayed rapid, disseminated tumor
growth, whereas mice treated with murPRAME-TCR T cells
had a significant and durable regression of their tumors and pro-
longed survival (Figures 5D–5F). Altogether, these data demon-
strate that PRAME can be effectively targeted as an adoptive
TCR cell therapy in these in vitro and in vivo models.
DISCUSSION
Here, we report one of the largest and most comprehensive im-
mune-transcriptomic landscape of extracranial pediatric solid




Figure 4. Tumor-specific gene expression
(A–C) Tumor-specific gene expression including (A) cell-surface proteins, (B) transcription factors, and (C) tumor germline antigens. Fill indicates that the gene is
overexpressed in the corresponding cancer type relative to normal tissues and has minimal expression in vital organs.
(D) mRNA expression of top genes for each category in each cancer type, vital organs, testes, ovary, and other normal tissues. Dots represent the median
expression for each cancer type.
(E) Representative PRAME immunohistochemistry in Ewing sarcoma and osteosarcoma demonstrates a robust expression of PRAME protein in tumor cells. H&E,
hematoxylin and eosin stain.




tumors, with data derived from 788 malignant samples including
657 solid tumor samples across 14 diagnoses from 623 pediatric
and young adult patients and 131 commonly used cancer cell
lines. Success with checkpoint inhibitor therapy in many cancer
types has led to an increased desire to understand the tumor-im-
mune microenvironment interactions. Toward this end, we
describe the immunogenomic landscape of our cohort of pediat-
ric solid malignancies including tumor-infiltrating lymphocyte
composition, cancer germline antigen and cell-surface protein
expression, immune checkpoint expression, and T cell receptor
repertoire. Notably, we observed a substantial degree of intra-
histologic variance in all immunogenomic features evaluated,
suggesting that histology alone may be insufficient for immuno-
therapeutic selection or trial design in these diseases. Broadly,
we note a generally lower level of immune cell infiltration in
most pediatric solid tumors compared to common adult tumors,
with a notable exception of ASPS.
A high tumor mutation burden (TMB) has been associated with
clinical response to checkpoint inhibition (Chan et al., 2019). Pe-
diatric cancers typically have a low somatic mutation burden
relative to common adult cancers (Gröbner et al., 2018; Ma
et al., 2018); however, we have previously reported that the
TMB in relapsed samples can increase two to three times
compared to their primary tumors (Chang et al., 2016; Eleveld
et al., 2015). Nonetheless, some cancers with low TMB such
as clear cell renal cell carcinoma show a strong intratumor im-
mune-related cytolytic activity and prominent immune infiltrate,
findings that may be related to their clinical responsiveness to
immune checkpoint inhibitors (Miao et al., 2018). These results
emphasize that TMBmay not be the only source of immunogenic
triggers. Notably, ASPS, a disease recently found to be highly
responsive to immune checkpoint inhibition (Wilky et al., 2019),
was observed in our study to be among the highest degree of
baseline TIL infiltrate despite being a low-TMB fusion-drivenma-
lignancy. Intra-tumoral T cell receptor clonality has been associ-
ated with clinical outcomes in metastatic cancers (Tumeh et al.,
2014) and in the setting of immunotherapies (Zhang et al., 2020).
Utilizing TCR prediction methodology to assess intra-tumoral
clonotypes, wewere able to demonstrate cases of robust expan-
sion of TCR clones in 5.8% of patients, occurring at the highest
frequency in ASPS and OS tumors, which suggests that a subset
of pediatric solid tumors aremore primed for immunotherapeutic
interventions.
A striking finding from this study is the identification of high
median T cell infiltration in OS relative to other pediatric solid tu-
mors and a significant correlation between immune cell infiltrate
and patient survival. We further show that CD8+ T cell infiltration
is independent of metastasis, a known predictor of poor out-
comes. Prior reports have also demonstrated robust immune
cell infiltrate and PD-L1 expression in a subset of OS, though
studies have conflicted results regarding the correlation between
these immunologic features and patient outcomes (Thanindra-
tarn et al., 2019; Wunder et al., 2020). In contrast to these
immunologically favorable observations, we also observed pro-
nounced expression of many additional immune inhibitory
signaling molecules in osteosarcoma tumors, including TGFB1
and CSF1R. Our findings are congruent with a previous analysis
in osteosarcoma that utilizes a partially overlapping osteosar-
coma cohort in the Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) dataset (Wu et al.,








(IC50 nM) Other cancers presenting same peptide
PRAME ALLPSLSHC HLA-A*02:01 2.72 467.3 melanoma (Gloger et al., 2016)
SLLQHLIGL HLA-A*02:01 0.12 9.9 melanoma (Gloger et al., 2016; Bassani-Sternberg et al., 2016)
MAGEA1 KVLEYVIKV HLA-A*02:01 0.05 5.9 Melanoma (Bassani-Sternberg et al., 2016; Pritchard et al., 2015)
MAGEA1/A4/A8 AETSYVKVL HLA-B*44:02 0.09 72.4 melanoma (Pritchard et al., 2015), breast cancer (Ternette
et al., 2018)
MAGEB2 GVYDGEEHSV HLA-A*02:01 2.44 386.5 chronic myeloid leukemia (Hassan et al., 2013)
MAGED2 NADPQAVTM HLA-C*05:01 0.08 172.1 breast cancer (Ternette et al., 2018; Rozanov et al., 2018), chronic
lymphocytic leukemia (Nelde et al., 2018)
PBK SYQKVIELF HLA-C*07:04 0.65 7398.1 breast cancer (Ternette et al., 2018; Rozanov et al., 2018),
glioblastoma (Shraibman et al., 2019), melanoma (Pritchard et al.,
2015; Bassani-Sternberg et al., 2017)
KREMEN2 ALGPPGAAL HLA-A*02:01 2.80 494.5 none reported
ULBP3 LLFDWSGTGRA HLA-A*02:01 2.74 473.5 colon cancer (Bassani-Sternberg et al., 2015)
LLFDWSGTGRADA HLA-A*02:01 2.81 498.4 colon cancer (Bassani-Sternberg et al., 2015)
IGF2BP3 KIQEILTQV HLA-A*02:01 0.23 17.7 melanoma (Gloger et al., 2016; Jensen et al., 2018), chronic
myeloid leukemia (Jensen et al., 2018), colon cancer (Murphy
et al., 2019), breast cancer (Ternette et al., 2018)
KIF20b AEIEDIRVL HLA-B*44:02 0.12 94.8 melanoma (Koumantou et al., 2019), chronic lymphocytic
leukemia (Nelde et al., 2018)
A summary table of high-affinity peptides in OS and EWS cells. Peptide percentage ranks and predicted HLA affinities were calculated using NetMHC
(Jurtz et al., 2017) with sequencing-identified HLA allele variants present in the corresponding cell line.




2020), which reported OS to be near the 50th percentile
compared to adult TCGA tumor types based on the rank order
of tumors by median immune score, and multiple immune inhib-
itory pathways were also noted to be active. Given the limited ef-
ficacy of immune checkpoint inhibitor monotherapy for OS in
clinical trials to date (D’Angelo et al., 2018a; Merchant et al.,
2016; Tawbi et al., 2017), these results suggest potential co-
inhibitory pathways in this disease that would make rationale tar-
gets for combination immunotherapies. (Song et al., 2021; Wu
et al., 2020).
In addition to checkpoint blockade, directed immune targeting
of tumor expressed antigens is another broad strategy for cancer
immunotherapy. Toward this goal, we provide an overview of the
expressed antigens in our cohort that are predicted to be the
most translationally relevant due to differential expression from
normal tissues. Our results confirm many of the tumor germline
antigens that are in current clinical development, as well as a
broad landscape of additional targets. As proof of concept of uti-
lizing transcriptomics and immunopeptidomic approaches, we
identified PRAME as an immune target, a highly differentially ex-
pressed protein with its peptide presented on the cell surface in
the context of HLA-A2, the most frequent HLA allele in humans.
Despite minor nonspecific cytotoxicity, which is commonly
observed with infusion of UTD, our modified PRAME TCR-trans-
duced T cells showed significantly higher in vitro activity in both
OS and EWS cell line models, as well as significant potency
in vivo in a metastatic EWS mouse model. Importantly, our
data suggest that PRAME may be a broad, multi-cancer immu-
notherapy target in pediatric extracranial solid malignancies,
similar to efforts in hematologic malignancies where clinical trials
are underway (e.g., NCT02494167 and NCT02203903).
In summary, we describe here, one of the largest to date, tran-
scriptomics-derived immunogenomics surveys of extracranial
pediatric solid malignancies. We find significant correlations
Figure 5. Specific anti-tumor activity of engineered T cells targeting a PRAME MHC class 1 peptide
(A) Structure of engineered PRAME TCR and schema for testing the specificity and efficacy of murPRAME-TCR T cells.
(B) In vitro co-culture of T cells with reporter cell lines at different effector:tumor (E:T) ratios. Luminescence wasmeasured after 24 h of co-culture and reported as
mean ± SEM (n = 3); **p < 0.01, ***p < 0.001.
(C) Schema for treating metastatic EWS xenograft model with murPRAME-TCR T cells.
(D) Bioluminescence images of TC32-Luc:PRAME cells after IV injection and treatment with vehicle or T cells.
(E) Quantification of bioluminescence imagining reported asmean ± SEM (n = 8 per group). p values of UTD versus murPRAME-TCRmice displayed as *p < 0.05,
**p < 0.01.
(F) Kaplan-Meier analysis of mouse survival using log-rank test (n = 8 per group).




between immunogenomic features, such as immune cell infiltra-
tion, especially intra-tumoral clonal T cell infiltration, with patient
survival. We provide a landscape of expressed tumor antigens
that aremost likely to be amenable to immunotherapeutic target-
ing. We further provide orthogonal confirmation of transcrip-
tomic findings by evaluating the immunopeptidome of osteosar-
coma and demonstrate proof of concept in vitro cytotoxicity
using a transcriptomics-informed ACT approach. This work pro-
vides a critical framework for immune targeting of lowmutational
burden extracranial solid tumors using transcriptome
profiling data. Furthermore, a companion gene-expression data-
base (https://omics-oncogenomics.ccr.cancer.gov/cgi-bin/JK)
derived from this study with outcome data including overall
and event-free survival for osteosarcoma and neuroblastoma al-
lows further exploration of this rich dataset. Finally, we report on
an engineered TCR against PRAME can be developed for ACT
immunotherapy for patients with pediatric solid tumors with
HLA-A*02.
Limitations of the study
A limitation of our study is the availability of clinical outcomes
data in only two (NB and OS) tumor types studied. Despite
this, we have reported a consistent association between high im-
mune infiltrate and immune signatures score and favorable prog-
nosis in both osteosarcoma and neuroblastoma (Wei et al.,
2018), a result that remains significant even when accounting
for metastatic disease status. Despite the consistency observed
in these two tumor types, we cannot evaluate whether this is a
universal finding among pediatric solid tumor types or specific
to these two diseases.
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Reagent or resource Source Identifier
Antibodies
Anti-CD3 Leica Biosystems Clone PS1
Anti-CD8 Cell Marque Clone C8144B
Anti-CD163 Leica Biosystems Clone Novasasta10D6
Anti-PD-L1 Spring Bioscience Clone SP142
Anti-PD-L1 isotype control Spring Bioscience Clone SP137
Pan-reactive for MHC class I, clone W6/32 BioLegend Cat. 311405
Anti-HLA*A2, clone BB7.2 BioLegend Cat. 343308
Anti-FLAG, clone L5 BioXcell Cat. 637304
Anti-tEGFR BioLegend Cat. 352903
Anti-PRAME Abcam Cat. ab219650
Chemicals, peptides, and recombinant proteins
TruSeq Stranded mRNA library Prep kits Illumina https://www.illumina.com/products/
by-type/sequencing-kits/library-
prep-kits/truseq-stranded-mrna.html




XenoLight D-Luciferin Potassium Salt Perkin Elmer Cat. 122799-5
Critical commercial assays
Nanostring GeoMx Digital Spatial Profiler (DSP) Nanostring https://www.nanostring.com/
products/geomx-digital-spatial-
profiler/geomx-dsp-overview/
V-PLEX human cytokine assay Meso Scale Diagnostics Cat. K151AOH-2
Steady-Glo Luciferase Assay System Promega E2520
Deposited data
dbGAP phs001928 for pediatric cancers This study https://www.ncbi.nlm.nih.gov/gap/
dbGaP phs000466 for CCSK (Gooskens et al., 2015) https://www.ncbi.nlm.nih.gov/gap/
dbGaP phs000467 for NBL (Wei et al., 2018) https://www.ncbi.nlm.nih.gov/gap/




dbGaP phs000720 for RMS (Shern et al., 2014) https://www.ncbi.nlm.nih.gov/gap/
dbGaP phs000768 for EWS (Brohl et al., 2014) https://www.ncbi.nlm.nih.gov/gap/
dbGaP phs001052 for Omics study (Chang et al., 2016) https://www.ncbi.nlm.nih.gov/gap/
Gene expression of neuroblastoma cell lines;
GEO GSE89413
(Harenza et al., 2017) https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE89413
Immunopeptidomes data osteosarcoma cell lines https://www.ebi.ac.uk/pride Accession: PXD017130
Experimental models: Cell lines
ASPS4c159 This study N/A
CC-A This study N/A
FUUR1 This study N/A
NCIEWS5000 This study N/A
6647 This study N/A
A673 This study N/A
(Continued on next page)





Reagent or resource Source Identifier
CHLA258 This study N/A
CHLA352 This study N/A
CHP100L This study N/A
SKES1 This study N/A
SKNLO This study N/A
SKNMC This study N/A
TC106 This study N/A
TC138 This study N/A
TC167 This study N/A
TC177 This study N/A
TC215 This study N/A
TC233 This study N/A
TC244 This study N/A
TC248 This study N/A
TC253 This study N/A
TC32 This study N/A
TC487 This study N/A
TC4C This study N/A
TTC466 This study N/A
TTC475 This study N/A
TTC547 This study N/A
CHP134 This study N/A
GILIN This study N/A
IMR32 This study N/A
IMR5 This study N/A
KCNR This study N/A
LAN1 This study N/A
LAN5 This study N/A
NB1691 This study N/A
SKNBE2 This study N/A
SKNDZ This study N/A
NBEB This study N/A
SHSY5Y This study N/A
SKNAS This study N/A
SKNFI This study N/A
SKNSH This study N/A
BIRCH This study N/A
CT-10 This study N/A
CTR This study N/A
RD This study N/A
RH1 This study N/A
RH18 This study N/A
RMS559 This study N/A
TTC-442 This study N/A
TTC-516 This study N/A
CW9109 This study N/A
JR This study N/A
MP4 This study N/A
NCI-ARMS1 This study N/A
(Continued on next page)





Reagent or resource Source Identifier
NCI-RMS-052 This study N/A
RH28 This study N/A
RH30 This study N/A
RH4 This study N/A
RH41 This study N/A
RH5 This study N/A
ASPS1 This study N/A
CHLA10 This study N/A
CHLA25 This study N/A
CHLA32 This study N/A
CHLA9 This study N/A
ES8 This study N/A
RDES This study N/A
TC71 This study N/A
HOS This study N/A
SAOS2 This study N/A
SJSA1 This study N/A
U2OS This study N/A
Hs729 This study N/A
RH36 This study N/A
SKNEP1 This study N/A
SKPNETLI This study N/A
TC240 This study N/A
7556 This study N/A
JR1 This study N/A
RH2 This study N/A
RH3 This study N/A
RMS-YM This study N/A
RUCH2 This study N/A
RUCH3 This study N/A
SCMC This study N/A
T91-95 This study N/A
TE617 This study N/A
H170 This study N/A
HR (Linardic et al., 2007) N/A
COGE352 (Teicher et al., 2015) N/A
ES1 (Teicher et al., 2015) N/A
ES2 (Teicher et al., 2015) N/A
ES3 (Teicher et al., 2015) N/A
ES4 (Teicher et al., 2015) N/A
ES6 (Teicher et al., 2015) N/A
ES7 (Teicher et al., 2015) N/A
EW8 (Teicher et al., 2015) N/A
CHA59 (Teicher et al., 2015) N/A
KHOS240S (Teicher et al., 2015) N/A
KHOS312H (Teicher et al., 2015) N/A
KHOSNP (Teicher et al., 2015) N/A
OHS (Teicher et al., 2015) N/A
HSSY11 (Teicher et al., 2015) N/A
(Continued on next page)





Reagent or resource Source Identifier
SW982 (Teicher et al., 2015) N/A
SYO1 (Teicher et al., 2015) N/A
CHP-212 (Harenza et al., 2017) N/A
COGN415 (Harenza et al., 2017) N/A
COGN440 (Harenza et al., 2017) N/A
COGN453 (Harenza et al., 2017) N/A
COGN471 (Harenza et al., 2017) N/A
COGN496 (Harenza et al., 2017) N/A
COGN519 (Harenza et al., 2017) N/A
COGN561 (Harenza et al., 2017) N/A
COGN573 (Harenza et al., 2017) N/A
KELLY (Harenza et al., 2017) N/A
NB1 (Harenza et al., 2017) N/A
NB1643 (Harenza et al., 2017) N/A
NBSD (Harenza et al., 2017) N/A
NGP (Harenza et al., 2017) N/A
NLF (Harenza et al., 2017) N/A
NMB (Harenza et al., 2017) N/A
SMSKAN (Harenza et al., 2017) N/A
SMSSAN (Harenza et al., 2017) N/A
COGN534 (Harenza et al., 2017) N/A
COGN549 (Harenza et al., 2017) N/A
FELIX (Harenza et al., 2017) N/A
LAN6 (Harenza et al., 2017) N/A
NB16 (Harenza et al., 2017) N/A
NB69 (Harenza et al., 2017) N/A
NBLS (Harenza et al., 2017) N/A
Experimental models: Organisms/strains




Lentiviral expression construct of a TCR which recognizes
the HLA*A2-restricted SLLQHLIGL peptide corresponding
to PRAME
(Amir et al., 2011) N/A
Lentiviral expression construct of luciferase and mCherry This study N/A
Lentiviral expression construct of luciferase and PRAME
cDNA with C-term V5 tag
This study N/A
Software and algorithms
NGS bioinformatic pipeline This study https://zenodo.org/record/5608456
R (3.3.1) https://www.r-project.org/




STAR (2.5.3a) (Dobin et al., 2013) https://github.com/alexdobin/STAR
GATK (3.8-1) (McKenna et al., 2010) https://gatk.broadinstitute.org
Tophat-Fusion (2.0.13) (Kim and Salzberg, 2011) https://ccb.jhu.edu/software/tophat/
fusion_index.shtml
FusionCatcher (1) (Nicorici et al., 2014) https://github.com/ndaniel/
fusioncatcher
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Javed
Khan (khanjav@mail.nih.gov).
Material availability
All stable reagents generated in this studywill bemade available from the lead contact on request after a completedmaterials transfer
agreement if there is potential for commercial application.
Data and code availability
d The raw RNA-seq data analyzed in this study are available from the public databases such as Gene Expression Omnibus (GEO;
GSE89413 and GSE84629 for NBL cell lines and RD cell line respectively) or the database of Genotypes and Phenotypes
(dbGaP; phs000466 for CCSK; phs000467 for NBL; phs000468 for OS; phs000720 for RMS, phs000768 for EWS;
phs001052 for Omics study; and phs001928 for the remainder). The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride) with the dataset identifier
PXD017130. Accession numbers are listed in the key resources table. The expression data for this study are available at the
Oncogenomics Expression Database (https://omics-oncogenomics.ccr.cancer.gov/cgi-bin/JK).
d Code of a custom bioinformatic pipeline to analyze RNA-seq data in this study is deposited at Zenodo (https://zenodo.org/
record/5608456)). An R package for Kaplan Meier optimization is available from https://zenodo.org/record/5610858.
d Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
All human specimens for sequencing were obtained from patients with appropriate consent approved by the Institutional Review
Board of the participating facilities and were deemed exempt by the Office of Human Subject Research. Tumors were classified
Continued
Reagent or resource Source Identifier
Star Fusion (1.3.1) (Haas et al., 2017) N/A
ssGSEA (Barbie et al., 2009) https://www.genepattern.org/modules/
docs/ssGSEAProjection/4
IntegrateNeo (1.2.0) (Zhang et al., 2017) https://github.com/ChrisMaherLab/
INTEGRATE-Neo
EdgeR (3.7) (Robinson et al., 2010) https://bioconductor.org/packages/
release/bioc/html/edgeR.html
MiXCR (3.0.10) (Bolotin et al., 2015) https://mixcr.readthedocs.io/en/latest/
vdjTools (1.2.1) (Shugay et al., 2015) https://vdjtools-doc.readthedocs.io/
en/master/
pVACTools (1.5.4) (Hundal et al., 2020) https://pvactools.readthedocs.io/en/
latest/index.html
Superheatmap (0.1.0) (Barter and Yu, 2018) https://cran.r-project.org/web/
packages/superheat/index.html
KM optimization (Wei et al., 2018) https://zenodo.org/record/5610858
PEAKS Studio Bioinformatics Solutions Inc. N/A
Other
cBioPortal Memorial Sloan Kettering Cancer
Center, New York, NY
http://www.cbioportal.org/
VDJdb web browser (Shugay et al., 2015) https://vdjdb.cdr3.net/
TCRb2010 (Warren et al., 2011) ftp://ftp.bcgsc.ca/supplementary/
TCRb2010/
Oncogenomics Expression Database This study https://omics-oncogenomics.ccr.cancer.
gov/cgi-bin/JK




by local pathological review using standard histologic techniques. For PRAME immunohistochemistry validation experiments, PDXs
from diagnostic biopsies or surgical excisions were generated following written informed consent to participate in an institutional
oncology specimen repository program; approval of these consents was obtained by the internal review board from Cincinnati Chil-
dren’s Hospital Medical Center (CCHMC IRB approved protocol number 2008-0021). Samples in this study were all de-identified,
therefore the age and gender of patients is not collected in this study. We performed RNA-seq on 935 samples in this study repre-
senting 657 pediatric extracranial solid tumors from 623 patients across 14 diagnoses and 147 normal human tissues.
Cell lines
WeperformedRNA-seq on 131 commonly used human pediatric cancer cell lines (Table S1). All cell lines used in this study have been
authenticated by either STR profiling or genotyping by sequencing.
Mouse xenograft model
Female 6-8 weeks old NSG (NOD.Cg-Prkdcscid Il2Rgtm1Wjl/SzJ) mice were used in Ewing sarcoma xenograft model to test antitumor
activities for T cells expressing a modified TCR. Animal studies were approved by the NCI Animal Research Advisory Committee and
conducted in accordance with Animal Welfare Regulations.
METHOD DETAILS
RNA sequencing
Total RNAs was isolated from freshly frozen tumors using RNeasy mini kits or AllPrep DNA/RNA mini kits (QIAGEN, Germantown,
MD). PolyA-selected or Ribozero-selected RNA libraries were prepared for RNA sequencing on Illumina HiSeq2000, 2500, and
NextSeq500 according to the manufactures protocol (Illumina, San Diego, CA). Sequencer-generated bcl files were converted to
fastq files using the bcl2fastq tool in CASAVA (Illumina, San Diego, CA) suite. Paired-end reads (100 bp for HiSeq2000, 125 bp
for HiSeq2500, and 80 bp for NextSeq500) were assessed for quality using FastQC and the average mapped unique reads in
this study is > 85 million for each sample (Table S1B). Fastq files were then mapped to GRCH37 reference genome using the
STAR/2.5.3a alignment algorithm (Dobin et al., 2013) and subsequently quantified by RSEM program (Li and Dewey, 2011) based
upon Ensembl GRCh37.75 gene annotation.
Single sample gene set enrichment analysis (ssGSEA)
Read counts for each gene between samples was normalized using TMMmethod implemented in edgeR (Robinson et al., 2010) and
then transformed to FPKM. This expression data was used to predict enrichment scores of twenty-four immune signatures obtained
from CIBERSORT (Newman et al., 2015) and ESTIMATE (Yoshihara et al., 2013) packages using single-sample GSEA (ssGSEA) from
GenePattern (https://www.genepattern.org/modules/docs/ssGSEAProjection/4).
Kaplan Meier optimization
We used a KM optimization procedure, a computational technique for performing optimized Kaplan-Meier survival analysis on gene
expression-derived signatures (Wei et al., 2018). Briefly, for a given gene signature, this procedure finds an optimal cutoff for strat-
ifying patients into low-and high-risk groups that results in the maximal separation of the Kaplan-Meier survival curves and then es-
timates the statistical significance of this cutoff by means of the permutation test. This technique was implemented as an R package
available from https://github.com/ibkstore/kmcut. We performed the KM optimization on the osteosarcoma patient cohort where
outcome data were available.
Cancer-specific antigen analysis
Within each cancer diagnosis, gene expression of cell surface molecules, and cancer-specific transcription factors, tumor germline
antigens, were compared against normal tissue samples with thematching library prep using edgeR (Robinson et al., 2010) package.
The following criteria were used to select cancer-specific differentially expressed genes:
a) Differential gene expression P value (compare to all normal except testis & Ovary) % 0.00001
b) Differential gene expression LogFC (compare to All normal except testis & Ovary) R 4 (i.e., FC R 16-fold)
c) Expression in vital organs (Heart and Brain) < 1 FPKM
d) Expression in Tumor R 5 FPKM
T cell receptor analysis
Transcriptome sequencing reads from tumor samples were aligned to V, D, J and C genes of T cell receptors and subsequently
assembled to extract TCR sequences using MiXCR 3.0.10 (Bolotin et al., 2015). Post processing of the later repertoire data was
performed using VDJtools1.2.1 (Shugay et al., 2015). For downstream analysis, we considered only TRB-CDR3 amino acid
sequences.





We validated our RNA-seq findings on an independent neuroblastoma tissue array (Saletta et al., 2017) using a multiplex protein
detection assay (Nanostring). After deparaffinized and rehydrated, Formalin-fixed paraffin-embedded (FFPE) tissue cores were incu-
bated with a cocktail of 61 primary antibodies which have their own unique and UV photocleavable indexing oligo, and 2 fluorescent
markers (CD45 and Tyrosine). After overnight incubation, the slides were stained with Syto83 (nuclear DNA stain) for 15 mins before
image processing using Nanostring GeoMx Digital Spatial Profiler. Slides were loaded onto the stage of an inverted microscope and
wide field fluorescence imaging was performed with epi-illumination from visible LED light engine. 20x images from all the cores on
the TMAwere stitched together to yield a high-resolution image of the tissue area of interest. Regions of interest (ROIs) within 650mM
diameter circle were selected based on the fluorescent image, and UV LED light was collimated to be reflected from the digital micro-
mirror device (DMD) surface into the microscope objective and cleaved the oligoes from these primary antibodies. A microcapillary
tip collected cleaved oligoes into the paired wells in a 96-well plate. 2 mL of these cleaved oligoes were further hybridized with Nano-
string designed Tag-set. After overnight hybridization at 65C in a thermocycler, samples were pooled by column and processed
using the nCounter Prep Station and Digital Analyzer as per manufacturer instructions (Nanostring). Digital counts from tags corre-
sponding to protein probes were analyzed using IgG isotype background subtraction and z-scored normalized.
Immunohistochemistry analysis
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from primary bone osteosarcoma specimens were properly annotated by
pathologist, cut into 5mm sections, and mounted onto plus-charge glass slides. For each specimen staining with CD3 (clone PS1;
Leica Biosystems), CD8 (clone C8144B; Cell Marque), and CD163 (clone Novacastra10D6; Leica Biosystems) were performed ac-
cording to standard protocols. IHC for PD-L1 (Spring Bioscience, clone SP142) at 0.096 mg/mL and isotype control (Spring Biosci-
ence, clone SP137) at 1mg/mL were utilized(Sunshine et al., 2017). Whole slides scanning used Scanscope XT and digital pictures
were taken via the Indica Labs HALO digital image analysis platform.
MHC class I flow cytometry
Five osteosarcoma cell lines were stained with antibodies which is pan-reactive for MHC class I (clone W6/32, BioLegend Cat.
311405) or specific for HLA*A2 (clone BB7.2, BioLegend, Cat. 343308). Flow cytometry was performed using BD LSRFortessa
cell analyzer (BD Biosciences).
Peptide sequencing by tandem mass spectrometry
OsteosarcomaMHC class I bound peptides were isolated as described previously. Due to poor HLA*A2 IP efficiency using the sero-
type specific antibody (clone BB7.2), we synthesized a 3xFLAG-HLA*A2:01 lentiviral plasmid for HLA*A2:01 peptide identification.
Briefly, 2-5x108 cells were washed with ice-cold PBS and lysed in a mild lysis buffer (20mM Tris-HCL pH = 8.5, 100mM NaCl,
1 mM EDTA, 1% Triton X-100, 1:80 Halt Protease Inhibitor). Lysates were sonicated, clarified by centrifugation for 1 hour at
20,000 g at 4C, and immunoprecipitated with anti-panMHC class I (clone W6/32, BioXcell, Cat. BE0079) or anti-FLAG (clone L5,
BioXcell, Cat. 637304) coupled protein G agarose (ThermoFisher, Cat. 22851). MHC complexes were washed and eluted in
0.15% trifluoroacetic acid in water. MHC bound peptides were isolated using C18 solid phase extraction columns (Sigma, Cat.
52601-U) and further purified by C18 spin tips (ThermoFisher, Cat. 84850) according to the manufacturer’s instructions.
Purified HLA-associated peptides were sequenced by tandem mass spectrometry (MS) using an Orbitrap Q-Exactive HF mass
spectrometer (Thermo Scientific, Waltham, MA). Briefly, peptides were separated on a reverse phase C18 Nano column (75mm 3
250mm, 2 mm particle) using a 90-minute effective gradient with 4%–35% phase B (0.1% formic acid in acetonitrile) on an Ultimate
3000 Nano liquid chromatography (Thermo Scientific, Waltham, MA). Data dependent acquisition mode was used to profile the HLA
peptidome. MS full scan range was 375-1650 m/z at resolution 120,000, and the top 15 most abundant peaks with assigned charge
state 1-4 were selected for MS/MS fragmentation using high collision dissociation (HCD) at resolution 30,000 andmaximum injection
time was 200 ms, isolation window was 1.4 m/z, and dynamic exclusion was set to 20 s. The peptide sequence alignment was map-
ped by PEKAS studio (Tran et al., 2019) (Version 8.5, Bioinformatics Solutions Inc.) using UniProtKB human proteome sequence
database (released on Feb 7th 2017). In the PEAKS searching engine, no enzyme digestion (for natural peptides), the Orbi-Orbi
HCD fragmentation, no variable modification, and de novo sequencing (library free search) were selected. The precursor mass toler-
ancewas 15ppm and fragment ion tolerancewas 0.5Da. The false discovery rate (FDR) was estimated by decoy-fusion database and
was set to 5%. Selected peptides tandem mass spectrum was visualized and manually inspected to assure the data quality.
Modification of TCR against PRAME
Wemodified a TCR which recognizes the HLA*A2-restricted SLLQHLIGL peptide (Amir et al., 2011) by exchanging the constant do-
mains of the TRAV and TRBV alleles with the murine equivalent TCR constant domains as previously described (Cohen et al., 2006) .
In addition, to increase the pairing between exogenous TCRa and TCRb, cysteine substitutions were included in the murine constant
domains of both the TRAV (T/C) and TRBV (S/C) positions 47 and 57 of the mouse constant domains, respectively (Cohen et al.,
2007). After design, codon-optimized sequenceswere synthesized (Genscript) and cloned downstream of the EF1a promoter. Cleav-
able 2A peptide sequences were used for co-expression of TRAV, TRBV and truncated EGFR.




Generation of reporter cell lines
Stable expression of firefly luciferase andmCherry or PRAMEwas performed by lentiviral transduction of cells with pLenti_luciferase-
p2a-mCherry or pLenti_luciferase-p2a-PRAMEv5tag lentivirus. In brief, lentiviral packaging was performed in LentiX-293T (Takara
Clontech) cells by co-transfection with a luciferase transfer plasmid along with psPax2 (Addgene #12260) and pMD2.G (Addgene
#12259). HLA*A2:01 positive, PRAME negative cell lines SAOS2 and TC32 were transduced with diluted lentiviral supernatant sup-
plemented with polybrene. Stable expression was achieved by selection for geneticin for at least 7 days.
Generation of transduced T cells
Leukapheresis samples from two healthy donors were purchased from the NIH Blood Bank (Bethesda, MD). Peripheral blood mono-
nuclear cells (PBMC) were isolated using Histopaque (Sigma, Cat. 10771). T cells were stimulated using CD3/CD8 Dynabeads (In-
vitrogen, Cat. 11131D) in the presence of IL-2 (40IU, PeproTech, Cat. 200-02). After 48 hours of stimulation, T cells were transduced
with a lentiviral vector containing truncated EGFR and murPRAME-TCR. Transduction efficiency was determined 4 days after trans-
duction by flow cytometry using a tEGFR antibody (BioLegend, Cat. 352903).
In vitro T cell cytotoxicity assays and cytokine quantification
T cells (day 9 post stimulation) were co-cultured with 5,000 target cells in 96-well plates. T cell to target cell ratio (E:T) was determined
based on transduction efficiency. After 24 hours, luciferase activity wasmeasured using Steady-Glo Luciferase Assay (Promega, Cat.
E2520). Experiment was performed in triplicate. For U2OS cytotoxicity assays, U2OS cells were seeded in 96 well plates and allowed
to attach for 6 hours. Relative cell confluency was quantified using the xCELLigence RTCA MP instrument (ACEA biosciences, Inc.).
Media or T cells were then added to wells at an effector:tumor ratio of 3:1. Data were acquired at 15-minute increments for 30 hours
and an unpaired t test at the final time point was used for statistical analysis. For cytokine analyses, effector and target cells were co-
cultured at a 3:1 ratio for 18 hours. Supernatants were collected and IFNg was quantified using the V-PLEX human cytokine assay
(Meso Scale Diagnostics, Cat. K151AOH-2).
Ewing Sarcoma xenograft model with adoptive T cell transfer
Animal studies were approved by the NCI Animal Research Advisory Committee and conducted in accordance with Animal Welfare
Regulations. For xenograft studies, 23 106 human Ewing sarcoma cell line TC32 expressing luciferase and PRAMEwere injected via
tail vein into NSG mice. Tumor burden was monitored by bioluminescence imaging using the Perkin Xenogen IVIS Imaging System
with 150mg/kg D-Luciferin (PerkinElmer, Cat. 122799-5). Mice were imaged 3 hours after TC32 injection to acquire baseline lumines-
cence and then randomized into 3 groups treated with saline (n = 8), untransduced T cells (n = 8), or murPRAME-TCR T cells (n = 8). A
total of 106 UTD or murPRAME-TCR T cells were injected via tail vein for the T cell treatment groups. Unpaired t tests were performed
at each time point comparing bioluminescence between UTD and murPRAME-TCR T cell treated mice. Kaplan Meier analysis was
performed using GraphPad PRISM using a three-way log-rank test.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification and statistical analyses used in this study is described in detail in the previous section. Differential gene expression
was quantified using edgeR (Robinson et al., 2010) package. Log-rank tests were performed in survival analyses using GraphPad
PRISM. One-factor and two factor Cox regression analysis of overall survival was used to examine if immunological features derived
from RNA-seq data are independent of tumor metastasis, a known outcome predictor. Cell viability or growth was measured using
Steady-Glo Luciferase Assay (Promega, Cat. E2520) or relative cell confluency using the xCELLigence RTCA MP instrument (ACEA
biosciences, Inc.) respectively. Tumor burden in mice was quantified by bioluminescence imaging using the Xenogen IVIS Imaging
System (PerkinElmer). Unpaired Student’s t test was used in T cell cytotoxicity, cytokine release, and monitoring tumor burden
experiments.
ADDITIONAL RESOURCES
Accompanying this analysis, we provide a companion Oncogenomics expression database (https://omics-oncogenomics.ccr.
cancer.gov/cgi-bin/JK) for all tumors, normal tissues, and commonly utilized cell lines in the research community. The data include
gene expression derived from the RNA-seq together with outcome data for osteosarcoma and neuroblastoma with capabilities for
Kaplan–Meier survival analysis and further data exploration.
Three databases are displayed:
1. Landscape - NCI; contains all RNA-seq data across all tumors, cell lines, and normal organs.
2. Landscape Neuroblastoma TARGET; Contains RNA-seq data for all Neuroblastoma tumors and cell lines.
3. Landscape Osteosarcoma TARGET; Contains RNA-seq data for all Osteosarcoma tumors and cell lines.




It allows users to search for individual genes of interest. The query results include heat-map and bar chart representations as well
as link-outs to more detailed annotations. As all datasets can be visualized as raw log2 (FPKM-TMM normalized) or pre-normalized
using Z-score or median centering. All query results can be downloaded as text files. Gene set enrichment analyses (GSEA) against
lists of both curated and custom gene sets can be done at 1) Individual Sample where genes are ranged by the expression of all genes
in that sample, or 2) genes ranked by correlation with that gene. Landscape Neuroblastoma TARGET and Landscape Osteosarcoma
TARGET databases contain event-free and overall survival where the user can perform Kaplan-Meier analysis using median expres-
sion level for that gene or through a KM optimization process to identify the optimal threshold for gene expression as described
above.
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